Citations

Clear

13603 citation(s) found for "_, _".

441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
Cordoba, R., Perini, Guilherme Fleury , Jørgensen, Judit , Bijou, Fontanet , Munoz, J., Kim, W. S., Rao, P. , Moucheron, Bérengère de, Yang, Gang , Carrancio, Soraya , Sudhindra, Akshay, Voetsch, Jessica, Cordoba, R., Chavez, Julio C , Nastoupil, Loretta J. , Bories, Pierre , Zinzani, Pier Luigi , Munoz, J., Carpio, Cecilia del Carmen , Costa, Alfredo Cardoso , Pourdehnad, Michael , Michot, Jean‐Marie

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_441 Get It

850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA
Perini, Guilherme Fleury , Neto, Abrahão Elias Hallack , Rao, P. , Mikita-Geoffroy, Joanna, Sudhindra, Akshay, Zinzani, Pier Luigi , Villasboas, José C. , Davies, Andrew , Kwiatek, M., Kridel, Robert , Andreadis, Charalambos Babis

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_850 Get It

893 | THE SAFETY AND FEASIBILITY OF INTRAVENOUS VESICULAR STOMATITIS VIRUS, AN IMMUNOGENIC ONCOLYTIC VIRUS, AS A TREATMENT FOR SPONTANEOUS AGGRESSIVE LYMPHOMA IN COMPANION DOGS
Reid, Kelly, Feiock, Caitlin, Büettner, Manuela , Pracht, Sara, Luethcke, Kristofer Ross , Seelig, Davis , Demos-Davies, Kimberly , Treeful, Amy E. , Henson, Morgan , Borgatti, A., Naik, Shobha, Winter, A., Buettner, M., Yung, C., Adams, R., Penza, V., Burt, L., Henson, M., Vallera, Daniel A. , Modiano, Jaime F. , Naik, S.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_893 Get It

A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
Wheless, Margaret C. , Gbolahan, Olumide B., Waechter, Blake, Ou, Fang‐Shu , Nixon, Andrew B. , Wilson, Luke, Ou, Fang-Shu , Nixon, Andrew B , Gbolahan, Olumide B , Zemla, Tyler , Hubbard, Joleen M. , Strickler, John H. , Wilson, Luke, Bekaii‐Saab, Tanios , Ciombor, Kristen K.

Mayo Clinic

The Oncologist | June 14, 2025 | Volume: 30 | Issue: 6 | Pages: No page available

10.1093/oncolo/oyaf069 | PMID 40515475 Get It

Abstract Background FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGFR1-3 inhibitor, in patients with metastatic or unresectable colorectal cancer whose tumors harbored FGF/FGFR alterations. Patients and Methods The ACCRU-GI-1701 is a single-arm phase II trial which enrolled patients with previously treated FGF/FGFR-altered metastatic colorectal cancer to receive oral pemigatinib daily in 21-day cycles. The primary endpoint is objective response. Secondary endpoints include clinical benefit, progression-free survival, overall survival, quality of life, and adverse events (AEs). This trial was registered with ClinicalTrials.gov (NCT04096417). Results Of the 14 patients included in the interim analysis, the objective response rate as well as clinical benefit rate were 0%. Given these results, the trial closed to enrollment after stage one due to futility. A total of 42.9% of patients had at least one grade 3 or higher AE, the most common being anemia and fatigue. Conclusion Pemigatinib monotherapy did not lead to objective responses in patients with chemorefractory metastatic colorectal cancer harboring FGF/FGFR alterations, although it was overall relatively well tolerated with no new safety signals. Notably, 93% (n = 13) of patients had only FGF/FGFR mutations and amplifications; one patient had an FGFR3-WHSC1 fusion at a low cfDNA percentage (0.02%).
The 4-Month Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis: A Word of Caution
Wilson, John W. , Temesgen, Zelalem , Gaensbauer, James , Gaensbauer, James T , Wilson, John W.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 13, 2025 | Volume: 211 | Issue: 8 | Pages: 1525-1525

10.1164/rccm.202501-0222le | PMID 40505145 Get It

EWSR1 Rearrangements in Basaloid Neoplasms With Adnexal Differentiation
Dehner, Carina , Agrawal, Shruti , Ameline, Baptiste , Gupta, Sounak , Halling, Kevin C. , Baumhoer, Daniel, Dehner, Carina A , Gupta, Sounak , Malik, Faizan Ahmad , Baumhoer, Daniel , Guo, Ruifeng

Mayo Clinic

Genes, Chromosomes and Cancer | June 13, 2025 | Volume: 64 | Issue: 6 | Pages: No page available

10.1002/gcc.70057 | PMID 40511965 Get It

ABSTRACTVarious cutaneous adnexal neoplasms have been associated with gene fusions as the main driver of their histogenesis, most of which showed poroid or hidradenomatous differentiation or represented other tumors of sweat glands. Recently, we encountered two cases of primitive basaloid neoplasms of predominantly folliculogenic/pilosebaceous origin, both surprisingly harboring recurrent EWSR1 rearrangements. Both tumors presented in young patients of either sex (1 F; 17 years; 1 M; 37 years) and involved the dermis and subcutaneous tissue of the abdominal wall (case 1) and the buttock (case 2). Histologically, the tumors were composed of primitive, basaloid cells with areas of keratinization (case 1) or foci of sebaceous differentiation (case 2) and stained strongly with keratins, p40 (case 1) or p63 (case 2), while lacking significant CD99 expression in both cases. Case 1 harbored an EWSR1::FLI1 fusion while case 2 harbored an EWSR1::PBX3 fusion. Clinical follow‐up was available for case 2 and showed no evidence of disease at 15 months of follow‐up. Methylation profiling showed case 1 to cluster with cutaneous squamous cell carcinoma, while case 2 was independent but positioned close to salivary gland epithelial‐myoepithelial carcinoma. These findings expand on the histopathologic and molecular genetic features of basaloid tumors with apparent adnexal differentiation and raise awareness to carefully interpret and correlate molecular findings with morphology and immunophenotype to avoid misinterpretation as a mesenchymal neoplasm.
Exploring the role of glucagon-like peptide-1 receptor agonists in critical illness: mechanisms, benefits, and clinical implications
Jogani, Vidit G., Edakkanambeth Varayil, Jithinraj, Elfadil, Osman Mohamed , Varayil, Jithinraj Edakkanambeth , Mundi, Manpreet S.

Mayo Clinic

Current Opinion in Critical Care | June 13, 2025 | Volume: 31 | Issue: 4 | Pages: 370-378

10.1097/mcc.0000000000001294 | PMID 40512576 Get It

Purpose of review This review aims to synthesize current evidence on the expanding role of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) beyond glycemic control, particularly in the context of critical illness. With growing recognition of their anti-inflammatory, immunomodulatory, and organ-protective properties, GLP-1RAs show promise in managing complications such as sepsis, acute respiratory distress syndrome (ARDS), acute kidney injury, and multiorgan dysfunction. This review explores their mechanisms across vital systems – including cardiovascular, pulmonary, renal, hepatic, neuropsychiatric, and gut-lung-microbiome axes – highlighting preclinical and clinical data. By consolidating emerging findings, this review aims to inform future translational research and support the integration of GLP-1RAs into critical care strategies. Recent findings Recent evidence highlights GLP-1RAs as promising adjuncts in critical illness due to their multiorgan protective effects. In cardiovascular systems, GLP-1RAs improve endothelial function, reduce ischemia-reperfusion injury, and modulate autonomic tone. In the CNS, they provide neuroprotection by reducing neuroinflammation and pyroptosis. In the lungs, they attenuate ARDS by decreasing cytokine production, enhancing surfactant secretion, and restoring alveolar-capillary integrity. Renally, they reduce acute injury and preserve filtration function. In the gut, GLP-1RAs modulate the microbiome, enhance barrier integrity, and lower systemic inflammation via the gut-lung axis. Additionally, they reduce hepatic inflammation and support pancreatic beta-cell survival, improving insulin sensitivity and metabolic stability in critical care. Summary GLP-1 receptor agonists hold promise as multiorgan protective agents in critical illness, offering benefits beyond glucose control. Their anti-inflammatory, metabolic, and vaso-protective properties may be harnessed to prevent or attenuate organ failure, support recovery, and improve long-term outcomes in critically ill patients. Further clinical trials are warranted to define their safety, efficacy, and optimal application across ICU populations.
Associations Between Esophageal Motility, Reflux, and Lung Mechanics and Function Are Disease-Specific, Both Between and Within Restrictive and Obstructive Lung Disease
Alghubari, Ali, Olson, Caroline , Bradley, Jessica , Cheah, Ramsah, Shah, Sadia , Naser, Abdel-Rahman N, Lee, Augustine S. , DeVault, Kenneth R. , Houghton, Lesley A. , Shah, Sadia Z. , Houghton, L A , Bradley, Jessica

Mayo Clinic

Clinical and Translational Gastroenterology | June 13, 2025 | Volume: 16 | Issue: 9 | Pages: e00874

10.14309/ctg.0000000000000874 | PMID 40512233 Get It

INTRODUCTION Gastroesophageal reflux is common in respiratory disease, but the interplay between gastrointestinal mechanisms that expose individuals to reflux and potentially aspiration, and lung mechanics and function remain incompletely understood. Our aim was to investigate this in patients with chronic obstructive pulmonary disease (COPD) and non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (non-IPF ILD), and compare with our published findings in IPF. METHODS Fifty-seven patients with COPD (aged: 34–75 years) and 64 with non-IPF ILD (22–75 years) who underwent high-resolution impedance manometry and 24-hour pH impedance together with pulmonary function assessment were compared with 35 IPF patients (51–84 years). RESULTS COPD patients were less likely to exhibit ineffective esophageal motility (IEM) and/or absent contractility ( P = 0.009; P = 0.028), and tended to exhibit esophagogastric junction outflow obstruction (EGJOO) and/or hypercontractility ( P = 0.09, P = 0.14) than IPF and non-IPF ILD patients. Notably, integrated relaxation pressure correlated with esophageal length index (ELI) ( P = 0.048) and inspiratory LESP ( P = 0.003), with latter 2 correlating with each other ( P < 0.001). EGJOO patients tended to have fewer proximal reflux events and reduced pulmonary function, with the latter inversely correlating with ELI ( P < 0.05). Non-IPF ILD patients were less likely to exhibit EGJOO than COPD patients ( P = 0.27), and less likely to exhibit IEM ( P = 0.07) than IPF patients. However, those with IEM or EGJOO exhibited greater proportions of reflux events reaching the proximal esophagus than those with normal motility ( P < 0.03), which in contrast to IPF, seemed not to associate with worse pulmonary function. DISCUSSION Associations between esophageal motility, and lung mechanics and function, and consequently reflux, are very disease-specific.
The Urology Care Hotel: Implementation of a New Model of Care for Postoperative Patients With Determination of Safety, Satisfaction, and Costs
Cabo, Jackson , Ashraf, Mahnoor, Giocondi, Lisa, Davis, Meghann E., Davis, Rebecca J., Humphreys, Mitchell R., Cabo, Jackson J S, Cabo, Jackson , Davis, Meghann E., Davis, Rebecca J., Humphreys, Mitchell R.

Mayo Clinic

Urology Practice | June 13, 2025 | Volume: 12 | Issue: 6 | Pages: 674-682

10.1097/upj.0000000000000851 | PMID 40512122 Get It